Source comparison
Hexarelin Dosage for Growth Hormone Release: Protocol Comparison
Low-Dose Maintenance 50–75mcg 2× daily 800–1,000% above baseline Minimal (>12 weeks) 8–12 weeks Insufficient for maximal GH release. Underdoses the receptor activation threshold. Best for long-term studies prioritizing sustained mild elevation over peak amplit
This comparison does not assign a generated winner or score.
- Low-Dose Maintenance
- 50–75mcg
- 2× daily
- 800–1,000% above baseline
- Minimal (>12 weeks)
- 8–12 weeks
- Insufficient for maximal GH release. Underdoses the receptor activation threshold. Best for long-term studies prioritizing sustained mild elevation over peak amplitude.
- Standard Research Protocol
- 100–150mcg
- 2–3× daily
- 1,200–1,600% above baseline
- 6–8 weeks
- 4–6 weeks on / 2–3 weeks off
- Gold standard for Hexarelin research. Maximizes GH pulse without premature desensitization. Cycling preserves receptor sensitivity across multiple research phases.
- High-Dose Acute Protocol
- 200–300mcg
- 1,400–1,800% above baseline
- 3–4 weeks
- 2–3 weeks maximum
- Produces marginally higher GH than 100–150mcg but accelerates tolerance onset by 50%. Only justified for short-duration studies where single-cycle maximum response is the endpoint.
- Continuous Non-Cycled
- 100–200mcg
- 1,200–1,600% initially, declining to 400–600% by week 8
- 6–10 weeks
- Not recommended beyond 6 weeks
- GH response degrades progressively without washout periods. By week 10, comparable studies show GH elevation drops to baseline despite continued administration.